Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exact Sciences Corporation
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.

Number of employees : 5 000 people.
Sales per Business
2020
Screening815.0754.7%
Precision Oncology440.4929.5%
COVID-19 Testing235.8315.8%
USD in Million
Sales per region
20192020Delta
United States864.8598.7%1 413.9194.8% +63.49%
Non-United States11.441.3%77.485.2% +577.07%
USD in Million
Managers
Name Title Age Since
Kevin Conroy Chairman, President & Chief Executive Officer 55 2014
Jeffrey Elliott Executive VP, Chief Operating & Financial Officer 43 2021
Graham Lidgard Chief Science Officer, SVP-Research & Development 72 2009
Sandra Statz Senior VP-Clinical & Regulatory Affairs - 2012
Gary Frings Chief Information Officer - 2015
Paul Limburg Co-Chief Medical Officer - 2018
Scott Johnson Senior Vice President-Research & Development - 2017
Steven Shak Co-Chief Medical Officer 70 2019
Tim Caprez Chief Compliance Counsel & Vice President - 2015
D. Coward Secretary, Chief Administrative Officer & SVP 56 2015
Members of the board
Name Title Age Since
Kevin Conroy Chairman, President & Chief Executive Officer 55 2014
Katherine S. Napier Independent Director 66 2009
Daniel Joseph Levangie Independent Director 71 2010
Thomas D. Carey Independent Director 59 2013
James Edward Doyle Lead Independent Director 75 -
Michael S. Wyzga Independent Director 66 2015
Kathleen Sebelius Independent Director 72 2019
Pierre Jacquet, Dr. Independent Director 54 -
Freda C. Lewis-Hall, Dr. Independent Director 66 2020
Shacey Petrovic Director 47 2020
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 18,505,044 10.7%
The Vanguard Group, Inc. 14,969,092 8.69%
ARK Investment Management LLC 11,728,629 6.81%
Wellington Management Co. LLP 6,799,864 3.95%
Capital Research & Management Co. (World Investors) 5,969,312 3.46%
Nikko Asset Management Co., Ltd. 4,679,730 2.72%
Baillie Gifford & Co. 4,452,527 2.58%
Nikko Asset Management Americas, Inc. 4,200,416 2.44%
SSgA Funds Management, Inc. 4,069,314 2.36%
JPMorgan Investment Management, Inc. 3,705,882 2.15%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exact Sciences Corporation